Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-023 in Advanced Hematologic Cancers
NCT06119685Phase 2Recruiting
- Sponsor
- Indapta Therapeutics
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of IDP-023 in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) (6 arms), sponsored by Indapta Therapeutics. Primary endpoints: Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1) at 1 year, Incidence of dose-limiting toxicities (DLTs) of IDP-023 Monotherapy - (Phase 1) at 21 days and 6 more. Started Oct 2023; status: recruiting.
02
Drugs
IDP-023
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06119685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06119685.